Use of stored serum from Uganda for development and evaluation of a human immunodeficiency virus type 1 testing algorithm involving multiple rapid immunoassays

Journal of Clinical Microbiology

Volumn 43, Issue 10, 2005, Pages 5312-5315

  Singer, Darrell E ^a   Kiwanuka, Noah ^b   Serwadda, David ^c   Nalugoda, Fred ^b   Hird, Linda ^d   Bulken Hoover, Jamie ^d   Kigozi, Godfrey ^b   Malia, Jennifer A ^a   Calero, Eva K ^a   Sateren, Warren ^a   Robb, Merlin L ^a   Wabwire Mangen, Fred ^c   Wawer, Maria ^e   Gray, Ronald H ^f   Sewankambo, Nelson ^c   Birx, Deborah L ^a   Michael, Nelson L ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b Rakai Health Sciences Project   (Uganda)

^c MAKERERE UNIVERSITY   (Uganda)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^e Columbia University Mailman School of Public Health ^*  (United States)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; ANTIBODY DETECTION; ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOASSAY; MASS SCREENING; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SERUM; UGANDA; VIRUS IDENTIFICATION;

AIDS SERODIAGNOSIS; ALGORITHMS; CONFIDENCE INTERVALS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOASSAY; SENSITIVITY AND SPECIFICITY; SERUM; SPECIMEN HANDLING; TIME FACTORS; UGANDA;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 26944448208     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.43.10.5312-5315.2005     Document Type: Article

References (15)

1. Birx, D. L., L. D. Loomis-Price, N. Aronson, J. Brundage, C. Davis, L. Deyton, R. Garner, F. Gordin, D. Henry, W. Holloway, T. Kerkering, R. Luskin-Hawk, J. McNeil, N. Michael, P. Foster Pierce, D. Poretz, S. Ratto-Kim, P. Renzullo, N. Ruiz, K. Sitz, G. Smith, C. Tacket, M. Thompson, E. Tramont, B. Yangco, R. Yarrish, R. R. Redfield, et al. 2000. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. J. Infect. Dis. 181:881-889.
2. Centers for Disease Control and Prevention. 2001. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm. Rep. 50:1-52.
3. Centers for Disease Control and Prevention. 1998. Update: HIV counseling and testing using rapid tests-United States, 1995. Morb. Mortal. Wkly. Rep. 47:211-215.
4. Foglia, G., G. D. Royster IV, K. M. Wasunna, R. Kibaya, J. A. Malia, E. K. Calero, W. Sateren, P. O. Renzullo, M. L. Robb, D. L. Birx, and N. L. Michael. 2004. Use of rapid and conventional testing technologies for human immunodeficiency virus type 1 serologic screening in a rural Kenyan reference laboratory. J. Clin. Microbiol. 42:3850-3852.
5. Giles R. E., K. R. Perry, and J. V. Parry. 1999. Simple/rapid test devices for anti-HIV screening: do they come up to the mark? J. Med. Virol. 59:104-109.
6. Henderson, D. K. 1999. Postexposure chemoprophylaxis for occupational exposures to the human immunodeficiency virus. JAMA 281:931-936.
7. Mellors, J. W., C. R. Rinaldo, Jr., P. Gupta, R. M. White, J. A. Todd, and L. A. Kingsley. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167-1170.
8. Nalugoda, F., R. H. Gray, D. Serwadda, N. K. Sewankambo, F. Wabwire-Mangen, N. Kiwanuka, T. Lutalo, G. Kigozi, C. Li, F. Makumbi, M. Kiddugavu, L. Paxton, S. Zawedde, and M. Wawer. 2004. Burden of infection among heads and non-head of rural households in Rakai, Uganda. AIDS Care. 16:107-115.
9. Spira, A. L, P. A. Marx, B. K. Patterson, J. Mahoney, R. A. Koup, S. M. Wolinsky, and D. D. Ho. 1996. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J. Exp. Med. 183:215-225.
10. Stickle, D. F., S. J. Pirruccello, S. Swindells, and S. H. Hinrichs. 2002. Discrepant results of 2 screening tests for anti-HIV antibody, Clin. Infect. Dis. 35:773-774; author reply 774-775.
11. mne infection depends critically on timing of initiation and duration of treatment. J. Virol. 72:4265-4273.
12. Urassa, W., K. Godoy, J. Killewo, G. Kwesigabo, A. Mbakileki, F. Mhalu, and G. Biberfeld. 1999. The accuracy of an alternative confirmatory strategy for detection of antibodies to HIV-1: experience from a regional laboratory in Kagera, Tanzania. J. Clin. Virol. 14:25-29.
13. van den Berk, G. E. L., P. H. J. Frissen, R. M. Regez, and P. J. G. M. Rietra. 2003. Evaluation of the rapid immunoassay Determine HIV 1/2 for detection of antibodies to human immunodeficiency virus types 1 and 2. J. Clin. Microbiol. 41:3868-3869.
14. Wawer, M. J., N. K. Sewankambo, S. Berkley, D. Serwadda, S. D. Musgrave, R. H. Gray, M. Musagara, R. Y. Stallings, and J. K. Konde-Lule. 1994. Incidence of HIV-1 infection in a rural region of Uganda. BMJ 308:171-173.
15. World Health Organization. 2004. Rapid HIV tests: guidelines for use in HIV testing and counselling services in resource-constrained settings. [Online.] http://www.who.int/hiv/pub/vct/en/rapidhivtestsen.pdf.